
SNSS
Healthcare · Biotechnology · $96.3M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · -79.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 24, 2021 | After the close | -0.96 | -0.21 | +78.2% |
| Nov 16, 2020 | After the close | -1.35 | -0.29 | +78.6% |
| Aug 11, 2020 | After the close | -1.93 | -0.60 | +68.8% |
| May 7, 2020 | After the close | -2.45 | -0.50 | +79.6% |
| Mar 10, 2020 | After the close | -2.63 | -0.50 | +81.0% |
| Nov 12, 2019 | Time not confirmed | -2.98 | -0.60 | +79.8% |
| Aug 7, 2019 | After the close | -3.50 | -0.90 | +74.3% |
| May 8, 2019 | After the close | -6.04 | -1.00 | +83.4% |
| Mar 7, 2019 | After the close | -7.44 | -1.60 | +78.5% |
| Nov 5, 2018 | After the close | -7.70 | -1.80 | +76.6% |
| Aug 7, 2018 | After the close | -8.93 | -2.00 | +77.6% |
| May 8, 2018 | After the close | -10.15 | -2.10 | +79.3% |
| Mar 8, 2018 | After the close | -8.75 | -2.10 |
As of February 24, 2021, Sunesis Pharmaceuticals, Inc. was acquired by Viracta Therapeutics, Inc., in a reverse merger transaction. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase…
| +76.0% |